mega-m headlin enbrel live rituxan
biosimilar
week review biotech coverag univers end week vs
nbi ytd vs nbi
notabl end week unconfirm spanish news headlin suggest
acquisit interest think unlik end week
resign announc cfo domin piscitelli compani sinc ipo
note event week
up pt reflect revis enbrel estim follow legal
victori vs sandoz addit conserv sale estim model see note
highlight week
rarx rarx announc receipt clinic mileston payment specifi merck
first patient dose macrocycl peptid compound extrem divers
platform non-compl cardiovascular target agreement rarx elig
receiv mileston payment
fda approv gener version kuvan manufactur pharma recal
enter patent settlement agreement allow market
gener version start oct
alxn/amgn spanish news outlet intereconoma unsubstanti articl
report talk acquir hefti premium current
price rang dont high confid credibl news sourc
made similar claim previous see fundament under-valued see
deal unlik analysi manag bd strategi suggest remain focus
therapeut technolog within core compet rare diseas plan
remain extrem disciplin execut acquisit recent year remain focus
indic total sale revenu line patient volum therapeut price
broad access larg popul rare diseas acquisit could
potenti solv on-going soliri ip litig challeng see prospect
pay outsiz premium difficult reconcil repeatedli
point evalu deal market volum valu line wherea
acquisit would complet u-turn approach addit note
potenti interest would like depend approach european patent offic epo rule
sep howev see under-valued given soliri ip competit overhang
see unlik cant complet rule possibl would bring
commerci strong rare-diseas hematolog portfolio
cfo domin piscitelli announc resign week effect sep
replac gener counsel eric loumeau exit cash hand
await readout gallop trial gpp
announc posit result studi demonstr clinic equival
rituxan rituximab biosimilar candid abp b-cell nhl trial second two
registr studi abp includ one ra demonstr clinic equival
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
rituxan biosimilar product approv far fda celltrion truxima
pfizer ruxienc subject undisclos launch date settlement
agreement roch rituxan us sale
constant currenc basi model biosimilar launch peak us sale
pend success regulatori review legal challeng roch
juli institut clinic econom review icer issu access
afford report warn benefit peanut protein desensit
outweigh project cost estim icer report
premis two point think misguid qol impact
publish remain uncertainti around long-term outcom toler
treatment actual present data european academi allergi
clinic immunolog eaaci congress demonstr posit impact qol
potenti long-term desensit on-going patient link eaaci note
also emphas icer branch fda opinion bear
drug access price continu see meaning advanc food
allergi field consist posit feedback kol therapeut potenti link
sf day link chicago day
gmab gmab present updat safety/efficaci data enapotamab vedotin
nsclc cohort on-going basket trial follow earlier dose escal data
present world confer lung cancer wclc sep
abstract releas enapotamab saw confirm orr advanc egfr wt
alk- nsclc patient post platinum-bas therapi
full present due sept
gmab darzalex plu vmp bortezomib melphalan prednison regimen approv
japan treatment frontlin multipl myeloma mm base data
gmab/sgen relapsed/refractori multipl myeloma rrmm set gsk bcma-
belantamab mafodotin collabor met primari endpoint
pivot trial triple-class refractori patient refractori imid proteasom
inhibitor darzalex see competit dara trial target rrmm patient
neulasta trx biosimilar fulphila trx
udenyca overal cgrp increas
among aimovig trx increas ajovi
decreas week emgal increas
overal trx w/w script
repatha class competitor praluent
repatha praluent
dupix
cabometyx trx compar unfavor overal
tki trx
auryxia trx
detail analysi pleas see joint noteworthi weekli rx trend note
drug price track drug price chang coverag week
exhibit weekli ytd perform
weekli perform trade near high obsv prqr trade
companytickerratingcurrentpriceptweekli returnytd jone industri nyse arca biotechnolog nasdaq biotechnolog ishar nasdaq biotechnolog specul risk exhibit drug price tracker
compani report pricerx capit market estim
